Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | BRD2 | P25440 | 2/20 | 0.33 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127983 | 1.00 | BRD4 (0.40) | BRD4CREBBPP2RY1LMNADDB1 | |
| SCHEMBL4127978 | 1.00 | BRD4 (0.40) | BRD4CREBBPP2RY1LMNADDB1 | |
| SCHEMBL4127974 | 1.00 | BRD4 (0.40) | BRD4CREBBPP2RY1LMNADDB1 | |
| SCHEMBL4135246 | 1.00 | BRD4 (0.40) | BRD4CREBBPP2RY1LMNADDB1 | |
| SCHEMBL7613136 | 0.81 | BRD4 (0.42) | BRD4CREBBPMEN1ALDH1A1MAPT | |
| SCHEMBL6278089 | 0.80 | LMNA (0.39) | BRD4CREBBPLMNADDB1CRBN | |
| SCHEMBL4123718 | 0.80 | LMNA (0.39) | BRD4CREBBPLMNADDB1CRBN | |
| SCHEMBL4197722 | 0.80 | LMNA (0.39) | BRD4CREBBPLMNADDB1CRBN | |
| SCHEMBL6975204 | 0.80 | LMNA (0.39) | BRD4CREBBPLMNADDB1CRBN | |
| SCHEMBL4127615 | 0.80 | LMNA (0.39) | BRD4CREBBPLMNADDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7504508-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7211672-B2 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740547-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-01-10 | — | — | EP | disclosed |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2006-05-18 | — | — | US | disclosed |
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2005-11-17 | — | — | US | disclosed |
| WO-2005100321-A1 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256158-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | BRD4 1768/4885CREBBP 432/4885P2RY1 387/4885 |
| US-20060106061-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | BRD4 1267/4885CREBBP 342/4885P2RY1 245/4885 |
| US-20090181966-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, LTB4R2, CYSLTR2 | BRD4 1768/4885CREBBP 432/4885P2RY1 387/4885 |
| US-20040082609-A1 | PGD2 receptor antagonists for the treatment of inflammatory diseases | PTGDR2, PTGDR, LTB4R2 | BRD4 1699/4885CREBBP 374/4885P2RY1 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.